CYDY CytoDyn Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$0.2

Period return

-0.06 (-21.92%)

Volume

1.7M

2026-07-21O $0.2 H $0.2 L $0.2 C $0.2MA5 $0.21MA20 $0.23MA60 $0.29MA120 $0.28

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 04. 08.High3 months ago
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2022. 02. 28.Medium4 years ago
2023년 3분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2021. 11. 30.Medium5 years ago
2023년 2분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2021. 08. 31.Medium5 years ago
2023년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2021. 02. 28.Medium5 years ago
2021년 3분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2020. 11. 30.Medium6 years ago
2021년 2분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2020. 08. 31.Medium6 years ago
2021년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2020. 07. 06.MediumHOLD6 years ago
HC Wainwright & Co.: Neutral
US analyst rating / recommendation change.
2020. 04. 28.LowBUY6 years ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2020. 04. 03.LowBUY6 years ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Rating & price-target changes

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Sector: Healthcare
Industry: Biotechnology
HQ: Vancouver, WA, United States
Fiscal year end: —
Employees: 13
IPO date: —

View details →

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 04. 08.	After market close (AMC)	—	—	—	—	—	Scheduled
FY2023 Q3	2022. 02. 28.	Time TBD	—	$-0.19	—	—	$266K	Reported
FY2023 Q2	2021. 11. 30.	Time TBD	—	$-0.13	—	—	$266K	Reported
FY2023 Q1	2021. 08. 31.	Time TBD	—	$-0.07	—	—	$41K	Reported

CytoDyn Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2020. 07. 06.	HC Wainwright & Co.	—	Downgrade	Buy → Neutral	—	HC Wainwright & Co.: Buy → Neutral
2020. 04. 28.	HC Wainwright & Co.	—	Maintain	— → Buy	—	HC Wainwright & Co.: Buy
2020. 04. 03.	HC Wainwright & Co.	—	Maintain	— → Buy	—	HC Wainwright & Co.: Buy
2019. 12. 19.	HC Wainwright & Co.	—	Maintain	— → Buy	—	HC Wainwright & Co.: Buy
2019. 09. 16.	HC Wainwright & Co.	—	Maintain	— → Buy	—	HC Wainwright & Co.: Buy